Boehringer Ingelheim Corporation Release: New Data show Striverdi® (olodaterol)* Respimat® Improves Exercise Tolerance in Patients With Moderate to Very Severe COPD1
The latest data from Phase III studies show that treatment with once-daily olodaterol Respimat® resulted in statistically significant improvements in the amount of time that patients with chronic obstructive pulmonary disease (COPD) could exercise before breathlessness forced them to stop.
Help employers find you! Check out all the jobs and post your resume.